Navigation Links
Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
Date:11/18/2013

served through 36 months in the MYDICAR high dose group are very encouraging," said Krisztina Zsebo, Ph.D., President and Chief Executive Officer of Celladon Corporation. "The continued clinical deterioration seen in the placebo patients receiving ongoing optimal standard therapy emphasizes the tremendous unmet medical need in people with advanced heart failure.'

In the additional two year follow up period of the CUPID 1 trial, the durability of reduced cardiovascular and terminal events previously observed in the MYDICAR high dose cohort at 12 months was maintained. The following recurrent cardiovascular and terminal events were tracked over the three years in all MYDICAR dose groups: myocardial infarction, worsening heart failure, heart failure-related hospitalization, left ventricular assist device (LVAD) placement, heart transplantation, and all-cause death. The risk of pre-specified recurrent cardiovascular events through full three years of follow up was reduced by 82% in the high dose group compared to the placebo group (p=0.048, where p-value is the statistical probability of a result due to chance alone).

In addition, the survival probability over time was higher for patients in all MYDICAR dose groups compared to the placebo group, especially in the high dose group. At three years post-administration, there were 13 deaths: six in the placebo group, three in the low-dose group, three in the mid-dose group and one in the high-dose group. Finally, persistence of the vector DNA as assessed by qPCR testing was demonstrated in three high dose MYDICAR patients in whom a biopsy was feasible, but not from patients in the placebo or lower dose groups.  No safety concerns were noted during the three year follow-up period.

About the CUPID 1 Trial

Phase 2a of the CUPID 1 trial was a clinical trial using Celladon's lead product candidate MYDICAR in patients with advanced heart failure. In this 39-patient tria
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
5. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
6. Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
7. Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
9. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
10. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
11. Neogen Corporation Announces 2nd Quarter Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... CollabRx, Inc. (NASDAQ: CLRX), a leading provider ... today announced that it will hold an investor conference ... financial results for the first quarter of fiscal 2015 ... the current fiscal year. , The dial-in number for ... 2014, at 5 p.m. EDT (2 p.m. PDT) is ...
(Date:7/31/2014)... 2014  Smith & Nephew (LSE:SN, NYSE: ... today announced its entry into the forefoot market ... Repair System. Comprised of three separate repair options, ... ligament repair and reconstruction, a metatarsal osteotomy guide, ... (PIP) fusion, also known as hammer toe correction. ...
(Date:7/31/2014)... Calif. (PRWEB) July 31, 2014 Held ... diagnosed patients with an overview of the disease and ... of drug side effects, as well as updates on ... grateful to Dr. Sandy Srinivas for organizing this educational ... of kidney cancer. “Sandy and her colleagues have put ...
(Date:7/31/2014)... The global market for molecular diagnostics ... according to a new study by Grand View Research, ... the subsequent introduction of advanced cancer diagnostic technologies are ... the next six years. Moreover, the growing global base ... coupled with disease triggering lifestyle habits such as smoking ...
Breaking Biology Technology:CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5
... ,The Wisconsin Biotechnology and Medical Device Association ... Marketing Communications to provide services to its members. ... state trade association and will hold workshops on branding ... organizations have also launched a Web site called ...
... I wrote about the emergence of some new angel groups in ... VCs and funds focused on early stage funding. I have been ... good reason for this as most of the Midwests biotech companies ... cousins. There has also been a dearth of funding for this ...
... week to merge its Imaging and Printing Group and its ... (IPSG) is a major milestone in HPs journey to become ... two units, HP has a unified and convincing product message ... the key that turns HPs consumer message into overdrive. , ...
Cached Biology Technology:Midwest angel investment in life sciences on the rise 2Midwest angel investment in life sciences on the rise 3Midwest angel investment in life sciences on the rise 4Midwest angel investment in life sciences on the rise 5Midwest angel investment in life sciences on the rise 6HP charges toward the living room 2HP charges toward the living room 3
(Date:7/31/2014)... step has been made to help better identify and treat ... abnormal narrowing and enlarging of medium sized arteries in the ... other organs causing damage. In a new report appearing in ... , scientists provide evidence that that FMD may not be ... show a connection to abnormalities of bones and joints, as ...
(Date:7/31/2014)... they are an iconic symbol of tropical resorts ... landscape. Some, like Hawaii,s State Flower- Hibiscus ... relatively few botanists and Hawaiian conservation workers, however, ... related group of plants known as Hibiscadelphus ... Hibiscus species are in fact highly endangered. Until ...
(Date:7/31/2014)... , July 31, 2014 NXT-ID, Inc., ... growing m-commerce market, reminds investors and consumers wanting ... wallet, Wocket™, that it will be on-air today, July ... Wocket smart wallet will be featured in a ... television show that airs on the History Channel, ...
Breaking Biology News(10 mins):Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2Brother of Hibiscus is found alive and well on Maui 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 3
... Bren School-based authors of a study published Jan. 20 in ... marine organisms resulting from exposure to a nanoparticle that had ... Lead author and assistant research biologist Robert Miller and ... professors and lead scientists at the UC Center for Environmental ...
... A molecule embedded in the membrane of human liver ... of hepatitis C virus, the first step in hepatitis C ... Chicago College of Medicine. The cholesterol receptor offers a ... drug may already exist, say the researchers, whose findings were ...
... The many factors that contribute to how cells communicate and ... understood, but researchers at Baylor College of Medicine ... fuse, and in the process, created a new physiological membrane ... edition of the journal PLoS Biology . "Within ...
Cached Biology News:Nano form of titanium dioxide can be toxic to marine organisms 2Entry point for hepatitis C infection identified 2Membrane fusion a mystery no more 2
Request Info...
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
Biology Products: